Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
J Histochem Cytochem ; 72(3): 173-188, 2024 03.
Article in English | MEDLINE | ID: mdl-38439738

ABSTRACT

Cisplatin (cPt) is a commonly used treatment for solid tumors. The main target of its cytotoxicity is the DNA molecule, which makes the DNA damage response (DDR) crucial for cPt-based chemotherapy. Therefore, it is essential to identify biomarkers that can accurately predict the individual clinical response and prognosis. Our goal was to assess the usefulness of alkaline comet assay and immunocytochemical staining of phosphorylated Hsp90α (p-Hsp90α), γH2AX, and 53BP1 as predictive/prognostic markers. Pre-chemotherapy peripheral blood leukocytes were exposed to cPt in vitro and collected at 0, 24 (T24), and 48 (T48) hr post-drug removal. Healthy subjects were also included. Baseline DNA damage was elevated in cancer patients (variability between individuals was observed). After cPt, patients showed increased γH2AX foci/nucleus (T24 and T48). Both in healthy persons and patients, the nuclear p-Hsp90α and N/C (nuclear/cytoplasmic) ratio augmented (T24), decreasing at T48. Favorable clinical response was associated with high DNA damage and p-Hsp90α N/C ratio following cPt. For the first time, p-Hsp90α significance as a predictive marker is highlighted. Post-cPt-DNA damage was associated with longer disease-free survival and overall survival. Our findings indicate that comet assay and p-Hsp90α (a marker of DDR) would be promising prognostic/predictive tools in cP-treated cancer patients.


Subject(s)
Cisplatin , Neoplasms , Humans , Comet Assay , Cisplatin/pharmacology , Cisplatin/therapeutic use , Neoplasms/drug therapy , Neoplasms/genetics , DNA Damage , Leukocytes
3.
Appl Immunohistochem Mol Morphol ; 30(6): 425-434, 2022 07 01.
Article in English | MEDLINE | ID: mdl-35639358

ABSTRACT

Platinum analogs are commonly used for cancer treatment. There is increasing interest in finding biomarkers which could predict and overcome resistance, because to date there is no reliable predictive/prognostic marker for these compounds. Here we studied the immunohistochemical expression of proteins involved in DNA damage response and repair (γH2AX, 53BP1, ERCC1, MLH1, and MSH2) in primary tumor tissues from patients treated with platinum-based chemotherapy. Levels and localization of Heat Shock Protein (HSP)27 and phospho-(Thr5/7)-HSP90α (p-HSP90α) were also determined. The implications in clinical response, disease-free survival and overall survival were analyzed. High γH2AX and 53BP1 expressions were associated with poor clinical response. Nuclear p-HSP90α, as well as nuclear absence and low cytoplasmic expression of HSP27 correlated with good response. Patients with high γH2AX and high cytoplasmic HSP27 expressions had shorter overall survival and disease-free survival. MLH1, MSH2, or ERCC1 were not associated with clinical response or survival. We report the potential utility of p-HSP90α, HSP27, γH2AX, and 53BP1 as predictive/prognostic markers for platinum-based chemotherapy. We present the first study that evaluates the predictive and prognostic value of p-HSP90α in primary tumors. Our research opens new possibilities for clinical oncology and shows the usefulness of immunohistochemistry for predicting chemotherapy response and prognosis in cancer.


Subject(s)
HSP27 Heat-Shock Proteins , Neoplasms , Antineoplastic Agents/therapeutic use , Biomarkers , Biomarkers, Tumor/metabolism , DNA Damage , DNA-Binding Proteins/genetics , Endonucleases/metabolism , HSP27 Heat-Shock Proteins/genetics , Heat-Shock Proteins/genetics , Humans , MutS Homolog 2 Protein/genetics , Neoplasms/diagnosis , Neoplasms/drug therapy , Platinum Compounds/therapeutic use , Prognosis
4.
Breast Cancer Res Treat ; 194(2): 403-412, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35610400

ABSTRACT

PURPOSE: PALB2 variants have been scarcely described in Argentinian and Latin-American reports. In this study, we describe molecular and clinical characteristics of PALB2 mutations found in multi-gene panels (MP) from breast-ovarian cancer (BOC) families in different institutions from Argentina. METHODS: We retrospectively identified PALB2 pathogenic (PV) and likely pathogenic (LPV) variants from a cohort of 1905 MP results, provided by one local lab (Heritas) and SITHER (Hereditary Tumor Information System) public database. All patients met hereditary BOC clinical criteria for testing, according to current guidelines. RESULTS: The frequency of PALB2 mutations is 2.78% (53/1905). Forty-eight (90.5%) are PV and five (9.5%) are LPV. Most of the 18 different mutations (89%) are nonsense and frameshift types and 2 variants are novel. One high-rate recurrent PV (Y551*) is present in 43% (23/53) of the unrelated index cases. From the 53 affected carriers, 94% have BC diagnosis with 14% of bilateral cases. BC phenotype is mainly invasive ductal (78%) with 62% of hormone-receptor positive and 22% of triple negative tumors. Self-reported ethnic background of the cohort is West European (66%) and native Latin-American (20%) which is representative of Buenos Aires and other big urban areas of the country. CONCLUSION: This is the first report describing molecular and clinical characteristics of PALB2 carriers in Argentina. Frequency of PALB2 PV in Argentinian HBOC families is higher than in other reported populations. Y551* is a recurrent mutation that seems to be responsible for almost 50% of PALB2 cases.


Subject(s)
Breast Neoplasms , Ovarian Neoplasms , Argentina/epidemiology , Breast Neoplasms/epidemiology , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Fanconi Anemia Complementation Group N Protein/genetics , Female , Genetic Predisposition to Disease , Germ-Line Mutation , Humans , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/genetics , Retrospective Studies
5.
Int J Gynaecol Obstet ; 158(1): 93-100, 2022 Jul.
Article in English | MEDLINE | ID: mdl-34652826

ABSTRACT

OBJECTIVE: To determine whether circulating heat shock proteins HSP27/HSPB1 and HSP90α/HSPC1 may be useful for early prediction of the occurrence of pre-eclampsia in asymptomatic women. METHODS: We have measured by ELISA the levels of HSPB1, HSPC1, and placental protein 13 (PP13) in serum samples from 44 women in the first trimester (10-12 weeks) and second trimester (17-20 weeks) of pregnancy. Western blot and immunohistochemistry for HSPB1 and HSPC1 were performed. RESULTS: HSPB1 serum levels were higher in women with pre-eclampsia than in normotensive pregnant women at the first and second trimester (P = 0.003), whereas PP13 levels decreased in women with pre-eclampsia only in the first trimester of gestation (P = 0.021). We also observed higher HSPB1 levels in patients with early-onset pre-eclampsia in the first and second trimester (P = 0.014). CONCLUSION: This pilot study points out that circulating HSPB1 levels in first and second trimester might be useful for predicting the occurrence of pre-eclampsia in asymptomatic women. Further validation studies are needed to finally establish this protein as a candidate predictive biomarker of pre-eclampsia.


Subject(s)
HSP27 Heat-Shock Proteins , Heat-Shock Proteins , Molecular Chaperones , Pre-Eclampsia , Biomarkers , Female , HSP27 Heat-Shock Proteins/blood , Heat-Shock Proteins/blood , Humans , Molecular Chaperones/blood , Pilot Projects , Placenta/metabolism , Pregnancy , Pregnancy Trimester, First , Pregnancy Trimester, Second
6.
Cancer Genet ; 260-261: 14-17, 2022 01.
Article in English | MEDLINE | ID: mdl-34801929

ABSTRACT

Double heterozygosity pathogenic variants in BRCA1 and BRCA2 genes are a very rare finding, particularly in non-Ashkenazi individuals. We described the first case of double heterozygosity variants in a non-Ashkenazi Argentinean woman with metachronous bilateral breast cancer. The proband is a 65-year-old female diagnosed with invasive ductal carcinoma in the left breast at 45 years old and invasive carcinoma in the right breast at 65 years old. She underwent a multi-gene panel testing indicating the presence of two concurrent heterozygous germline deleterious variants NM_007300.4(BRCA1):c.4201C>T (p.Gln1401Ter), and NM_000059.3(BRCA2):c.5146_5149del (p.Tyr1716fs). . The patient's son (40 years-old) was found to have the inherited pathogenic variant in BRCA2 gene. There are few reports of double heterozygosity variants in BRCA1 and BRCA2 genes in Latin America. The two pathogenic variants identified in our patient have not been described together so far.


Subject(s)
BRCA1 Protein/genetics , BRCA2 Protein/genetics , Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , Neoplasms, Second Primary/genetics , Point Mutation , Sequence Deletion , Adult , Aged , Female , Genetic Counseling , Genetic Predisposition to Disease , Genetic Testing , Heterozygote , Humans , Male , Pedigree , Sequence Analysis, DNA
7.
Oncotarget ; 9(41): 26527-26542, 2018 May 29.
Article in English | MEDLINE | ID: mdl-29899874

ABSTRACT

Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have therefore been developed. Despite this progress, not all patients respond to the treatment. Retinoic acid (RA) has been proposed as an adjuvant treatment of breast carcinoma because of its ability to inhibit cell growth. We evaluated the effect of Tz in combination with RA on the viability, adhesion, migration, invasion and expression of migration-related proteins in SKBR3 and BT-474 human breast cancer cells. MTT, pharmacological interaction analysis, immunofluorescence, adhesion/migration/invasion and Western blot assays were performed. The coadministration of both drugs synergistically decreased cell survival. Tz+RA significantly decreased adhesion/migration/invasion in both cell types. Tz+RA strongly reduced FAK and HER2 expression and induced nuclear FAK translocation. In addition, a granular distribution of HER2 receptor was observed after the combined treatment. In conclusion, the coadministration of both drugs in patients with this type of cancer could contribute to the improvement of their prognosis and reduce the adverse effects of therapy because the applied Tz doses would be lower due to the adjuvant effect of RA.

8.
J Clin Pathol ; 71(1): 52-58, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28743687

ABSTRACT

AIM: Accumulated evidence suggests that aberrant methylation of the TP73 gene and increased levels of ΔNp73 in primary tumours correlate with poor prognosis. However, little is known regarding the transcriptional and functional regulation of the TP73 gene in breast cancer. The aim of the present study was to determine the expression of the ΔNp73 isoform, its relationship with DNA methylation of TP73 and their clinical prognostic significance in breast cancer patients. METHODS: TP73 gene methylation was studied in TCGA datasets and in 70 invasive ductal breast carcinomas (IDCs). The expression of p73 isoforms was evaluated by immunohistochemistry (IHC) and Western blot and correlated with clinicopathological variables and clinical outcome. RESULTS: We observed that the methylation of diverse CpG islands of TP73 differed significantly between molecular subtypes. An inverse correlation was found between p73 protein expression and the methylation status of the TP73 gene. The expression of exon 3' of p73 (only expressed in ΔNp73) was significantly higher in patients with wild-type p53. Immunohistochemical analysis revealed that all p73 isoforms were localised in both the nuclear and cytoplasmic compartments. We confirmed a positive association between the expression of ∆Np73 and high histological grade. CONCLUSIONS: Our findings suggest that high expression of ΔNp73 could be used to determine the aggressiveness of IDCs and could be incorporated in the pathologist's report.


Subject(s)
Breast Neoplasms/diagnosis , Carcinoma, Ductal, Breast/diagnosis , CpG Islands/genetics , Tumor Protein p73/genetics , Breast/metabolism , Breast/pathology , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/pathology , DNA Methylation , Disease-Free Survival , Female , Humans , Immunohistochemistry , Prognosis , Protein Isoforms , Tumor Protein p73/metabolism
9.
Mol Cell Endocrinol ; 430: 1-11, 2016 07 15.
Article in English | MEDLINE | ID: mdl-27130522

ABSTRACT

Breast cancer is the most common malignancy in women, with metastases being the cause of death in 98%. In previous works we have demonstrated that retinoic acid (RA), the main retinoic acid receptor (RAR) ligand, is involved in the metastatic process by inhibiting migration through a reduced expression of the specific migration-related proteins Moesin, c-Src, and FAK. At present, our hypothesis is that RA also acts for short periods in a non-genomic action to cooperate with motility reduction and morphology of breast cancer cells. Here we identify that the administration of 10(-6) M RA (10-20 min) induces the activation of the migration-related proteins Moesin, FAK, and Paxillin in T-47D breast cancer cells. The phosphorylation exerted by the selective agonists for RARα and RARß, on Moesin, FAK, and Paxillin was comparable to the activation exerted by RA. The RARγ agonist only led to a weak activation, suggesting the involvement of RARα and RARß in this pathway. We then treated the cells with different inhibitors that are involved in cell signaling to regulate the mechanisms of cell motility. RA failed to activate Moesin, FAK, and Paxillin in cells treated with Src inhibitor (PP2) and PI3K inhibitor (WM), suggesting the participation of Src-PI3K in this pathway. Treatment with 10(-6) M RA for 20 min significantly decreased cell adhesion. However, when cells were treated with 10(-6) M RA and FAK inhibitor, the RA did not significantly inhibit adhesion, suggesting a role of FAK in the adhesion inhibited by RA. By immunofluorescence and immunoblotting analysis we demonstrated that RA induced nuclear FAK translocation leading to a reduced cellular adhesion. These findings provide new information on the actions of RA for short periods. RA participates in cell adhesion and subsequent migration, modulating the relocation and activation of proteins involved in cell migration.


Subject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Nucleus/metabolism , Focal Adhesion Protein-Tyrosine Kinases/metabolism , Microfilament Proteins/metabolism , Paxillin/metabolism , Tretinoin/pharmacology , Cell Adhesion/drug effects , Cell Line, Tumor , Cell Nucleus/drug effects , Female , HSP27 Heat-Shock Proteins/metabolism , HSP72 Heat-Shock Proteins , Humans , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Protein Transport/drug effects , Receptors, Retinoic Acid/agonists , Receptors, Retinoic Acid/metabolism , Retinoic Acid Receptor alpha/agonists , Retinoic Acid Receptor alpha/metabolism , Signal Transduction/drug effects , Tumor Suppressor Protein p53/metabolism , src-Family Kinases/metabolism
10.
Int J Hyperthermia ; 31(5): 464-75, 2015.
Article in English | MEDLINE | ID: mdl-26043026

ABSTRACT

PURPOSE: Hyperthermia is used in combination with conventional anticancer agents to potentiate their cytotoxicity. One of its key events is the synthesis of heat shock proteins (HSPs), which are able to associate with components from DNA repair mechanisms. However, little is known about their relationship with the mismatch repair system (MMR). Our aim was to study the effects of hyperthermia on cisplatin (cPt) sensitivity and to determine whether MLH1 and MSH2 associate with Hsp27 and Hsp72 in MMR-deficient(-)/-proficient(+) cells. MATERIALS AND METHODS: HCT116+ch2 (MMR-) and HCT116+ch3 (MMR+) cell lines were exposed to cPt with or without previous hyperthermia (42 °C, 1 h). Clonogenic survival assays, MTT, confocal immunofluorescence, immunoprecipitation, immunoblotting and flow cytometry were performed. RESULTS: Hyperthermia increased the cPt resistance in MMR- cells 1.42-fold. Immunofluorescence revealed that after cPt, Hsp27 and Hsp72 translocated to the nucleus and colocalisation coefficients between these proteins with MLH1 and MSH2 increased in MMR+ cells. Immunoprecipitation confirmed the interactions between HSPs and MMR proteins in control and treated cells. Hyperthermia pretreatment induced cell cycle arrest, increased p73 expression and potentiated cPt sensitivity in MMR+ cells. CONCLUSIONS: This is the first report showing in a MMR-/+ cellular model that MLH1 and MSH2 are client proteins of Hsp27 and Hsp72. Our study suggests that p73 might participate in the cellular response to hyperthermia and cPt in a MMR-dependent manner. Further functional studies will confirm whether HSPs cooperate with the MMR system in cPt-induced DNA damage response or whether these protein interactions are only the result of their chaperone functions.


Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/adverse effects , Colonic Neoplasms/drug therapy , DNA Damage/genetics , DNA Mismatch Repair/genetics , Fever/genetics , HSP27 Heat-Shock Proteins/metabolism , HSP72 Heat-Shock Proteins/metabolism , Cell Line, Tumor , Cisplatin/toxicity , Humans
11.
Med. oral patol. oral cir. bucal (Internet) ; 19(4): e359-e365, jul. 2014. ilus, tab
Article in English | IBECS | ID: ibc-124797

ABSTRACT

INTRODUCCIÓN: Cytokeratins (CK) are molecules of the cytoskeleton that contribute to the cellular differenciation. We studied the expression of CK1, CK13 and CK14 in thirty-three patients with OLP. The biopsied lesions were located in the dorsal surface of the tongue, the palatal keratinized mucosa and the nonkeratinized buccal mucosa. OBJECTIVES: This study aimed to determine the expression of CK1, CK13 and CK14 in oral lichen planus (OLP) and its relations with: clinical patterns, prognosis, drugs and tobacco intake and histopathological features. Study DESIGN: Immunohistochemical analysis, retrospective, descriptive, observational and no randomized study. RESULTS: No significant difference was observed in the expression of CK1 in patients with or without drug treatment. No association was found with the amount of drugs intake or smoking nor with the histopathological features examined. Samples immunostained with CK13 were all positive in the suprabasal layers, and 13 of them in the basal layer. In these last ones, statistical analysis showed significance in the grade of vacuolization of the basal layer (p = 0.023) and in the degree of exocytosis (p = 0.0025), this, making the degree of affection higher for both parameters. Thirty-two tissue sections were immunostained with CK14. CK14 was expressed in the basal layer in 97% of samples and in the suprabasal layer in 94% of samples. CONCLUSIONS: The three CK were altered in OLP. CK1 does not have a direct connection with the presence of of orthokeratosis. The finding of the CK13 in the basal layer is related to the agression of the lymphocytic infiltration in the epithelium, due to the basal stratum vacuolization and the increase in lymphocytic exocitosis. The presence of CK14 in the suprabasal stratums is not a parameter to predict malignancy. The CK in OLP do not follow the normal pattern of keratinized or non-keratinized mucosa


No disponible


Subject(s)
Humans , Keratins/ultrastructure , Lichen Planus, Oral/pathology , Early Detection of Cancer/methods , Exocytosis , Lymphocytes, Tumor-Infiltrating/pathology , Biomarkers, Tumor/analysis
12.
Neuro Oncol ; 16(11): 1499-509, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24968695

ABSTRACT

BACKGROUND: The brain is a common target of metastases for melanoma patients. Little is known about the genetic and epigenetic alterations in melanoma brain metastases (MBMs). Unraveling these molecular alterations is a key step in understanding their aggressive nature and identifying novel therapeutic targets. METHODS: Genome-wide DNA methylation analyses of MBMs (n = 15) and normal brain tissues (n = 91) and simultaneous multigene DNA methylation and gene deletion analyses of metastatic melanoma tissues (99 MBMs and 43 extracranial metastases) were performed. BRAF and NRAS mutations were evaluated in MBMs by targeted sequencing. RESULTS: MBMs showed significant epigenetic heterogeneity. RARB, RASSF1, ESR1, APC, PTEN, and CDH13 genes were frequently hypermethylated. Deletions were frequently detected in the CDKN2A/B locus. Of MBMs, 46.1% and 28.8% had BRAF and NRAS missense mutations, respectively. Compared with lung and liver metastases, MBMs exhibited higher frequency of CDH13 hypermethylation and CDKN2A/B locus deletion. Mutual exclusivity between hypermethylated genes and CDKN2A/B locus deletion identified 2 clinically relevant molecular subtypes of MBMs. CDKN2A/B deletions were associated with multiple MBMs and frequently hypermethylated genes with shorter time to brain metastasis. CONCLUSIONS: Melanoma cells that colonize the brain harbor numerous genetically and epigenetically altered genes. This study presents an integrated genomic and epigenomic analysis that reveals MBM-specific molecular alterations and mutually exclusive molecular subtypes.


Subject(s)
Brain Neoplasms/genetics , DNA Methylation , Gene Deletion , Melanoma/genetics , Mutation/genetics , Tumor Suppressor Proteins/genetics , Adult , Aged , Aged, 80 and over , Brain Neoplasms/mortality , Brain Neoplasms/secondary , Cohort Studies , Epigenesis, Genetic , Female , Follow-Up Studies , Humans , Liver Neoplasms/genetics , Liver Neoplasms/mortality , Liver Neoplasms/secondary , Lung Neoplasms/genetics , Lung Neoplasms/mortality , Lung Neoplasms/secondary , Male , Melanoma/mortality , Melanoma/pathology , Middle Aged , Neoplasm Staging , Prognosis , Survival Rate , Young Adult
13.
J Cell Mol Med ; 18(6): 1113-23, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24720764

ABSTRACT

Breast cancer is the most common malignancy in women and the appearance of distant metastases produces the death in 98% of cases. The retinoic acid receptor ß (RARß) is not expressed in 50% of invasive breast carcinoma compared with normal tissue and it has been associated with lymph node metastasis. Our hypothesis is that RARß protein participates in the metastatic process. T47D and MCF7 breast cancer cell lines were used to perform viability assay, immunobloting, migration assays, RNA interference and immunofluorescence. Administration of retinoic acid (RA) in breast cancer cells induced RARß gene expression that was greatest after 72 hrs with a concentration 1 µM. High concentrations of RA increased the expression of RARß causing an inhibition of the 60% in cell migration and significantly decreased the expression of migration-related proteins [moesin, c-Src and focal adhesion kinase (FAK)]. The treatment with RARα and RARγ agonists did not affect the cell migration. On the contrary, the addition of the selective retinoid RARß-agonist (BMS453) significantly reduced cell migration comparable to RA inhibition. When RARß gene silencing was performed, the RA failed to significantly inhibit migration and resulted ineffective to reduce moesin, c-Src and FAK expressions. RARß is necessary to inhibit migration induced by RA in breast cancer cells modulating the expression of proteins involved in cell migration.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Cell Movement/drug effects , Receptors, Retinoic Acid/metabolism , Tretinoin/pharmacology , Actin Cytoskeleton , Apoptosis/drug effects , Blotting, Western , Breast Neoplasms/metabolism , CSK Tyrosine-Protein Kinase , Cell Proliferation/drug effects , Female , Fluorescent Antibody Technique , Focal Adhesion Kinase 1/metabolism , Humans , Immunoenzyme Techniques , Microfilament Proteins/metabolism , RNA, Small Interfering/genetics , Receptors, Retinoic Acid/antagonists & inhibitors , Receptors, Retinoic Acid/genetics , Retinoids/pharmacology , Tumor Cells, Cultured , src-Family Kinases/metabolism
14.
Med Oral Patol Oral Cir Bucal ; 19(4): e359-65, 2014 Jul 01.
Article in English | MEDLINE | ID: mdl-24608215

ABSTRACT

UNLABELLED: INTRODUCCION: Cytokeratins (CK) are molecules of the cytoskeleton that contribute to the cellular differenciation. We studied the expression of CK1, CK13 and CK14 in thirty-three patients with OLP. The biopsied lesions were located in the dorsal surface of the tongue, the palatal keratinized mucosa and the nonkeratinized buccal mucosa. OBJECTIVES: This study aimed to determine the expression of CK1, CK13 and CK14 in oral lichen planus (OLP) and its relations with: clinical patterns, prognosis, drugs and tobacco intake and histopathological features. STUDY DESIGN: Immunohistochemical analysis, retrospective, descriptive, observational and no randomized study. RESULTS: No significant difference was observed in the expression of CK1 in patients with or without drug treatment. No association was found with the amount of drugs intake or smoking nor with the histopathological features examined. Samples immunostained with CK13 were all positive in the suprabasal layers, and 13 of them in the basal layer. In these last ones, statistical analysis showed significance in the grade of vacuolization of the basal layer (p=0.023) and in the degree of exocytosis (p=0.0025), this, making the degree of affection higher for both parameters. Thirty-two tissue sections were immunostained with CK14. CK14 was expressed in the basal layer in 97% of samples and in the suprabasal layer in 94% of samples. CONCLUSIONS: The three CK were altered in OLP. CK1 does not have a direct connection with the presence of orthokeratosis. The finding of the CK13 in the basal layer is related to the agression of the lymphocytic infiltration in the epithelium, due to the basal stratum vacuolization and the increase in lymphocytic exocitosis. The presence of CK14 in the suprabasal stratums is not a parameter to predict malignancy. The CK in OLP do not follow the normal pattern of keratinized or non-keratinized mucosa.


Subject(s)
Keratin-13/biosynthesis , Keratin-14/biosynthesis , Keratin-1/biosynthesis , Lichen Planus, Oral/metabolism , Adult , Aged , Aged, 80 and over , Female , Humans , Immunohistochemistry , Keratin-1/analysis , Keratin-13/analysis , Keratin-14/analysis , Lichen Planus, Oral/pathology , Male , Middle Aged , Retrospective Studies
15.
Cell Stress Chaperones ; 19(4): 493-505, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24307543

ABSTRACT

Neoadjuvant chemotherapy is used in patients with locally advanced breast cancer to reduce tumor size before surgery. Unfortunately, resistance to chemotherapy may arise from a variety of mechanisms. Heat shock proteins (HSPs), which are highly expressed in mammary tumor cells, have been implicated in anticancer drug resistance. In spite of the widely described value of HSPs as molecular markers in cancer, their implications in breast tumors treated with anthracycline-based neoadjuvant chemotherapy has been poorly explored. In this study, we have evaluated, by immunohistochemistry, the expression of HSP27 (HSPB1) and HSP70 (HSPA) in serial biopsies from locally advanced breast cancer patients (n = 60) treated with doxorubicin (DOX)- or epirubicin (EPI)-based monochemotherapy. Serial biopsies were taken at days 1, 3, 7, and 21, and compared with prechemotherapy and surgical biopsies. After surgery, the patients received additional chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil. High nuclear HSPB1 and HSPA expressions were found in invasive cells after DOX/EPI administration (P < 0.001), but the drug did not affect the cytoplasmic expression of the HSPs. Infiltrating lymphocytes showed high nuclear HSPA (P < 0.01) levels at postchemotherapy. No correlations were found between HSPs expression and the clinical and pathological response to neoadjuvant therapy. However, in postchemotherapy biopsies, high nuclear (>31 % of the cells) and cytoplasmic HSPA expressions (>11 % of the tumor cells) were associated with better DFS (P = 0.0348 and P = 0.0118, respectively). We conclude that HSPA expression may be a useful prognostic marker in breast cancer patients treated with neoadjuvant DOX/EPI chemotherapy indicating the need to change the administered drugs after surgery for overcoming drug resistance.


Subject(s)
Anthracyclines/therapeutic use , Antibiotics, Antineoplastic/therapeutic use , Breast Neoplasms/diagnosis , Breast Neoplasms/drug therapy , Breast/pathology , HSP70 Heat-Shock Proteins/analysis , Neoadjuvant Therapy , Adult , Aged , Breast/drug effects , Breast Neoplasms/pathology , Doxorubicin/therapeutic use , Epirubicin/therapeutic use , Female , Follow-Up Studies , HSP27 Heat-Shock Proteins/analysis , Humans , Immunohistochemistry , Middle Aged , Prognosis
16.
Reproduction ; 146(3): 233-42, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23904563

ABSTRACT

Mammary stroma is composed of various cell types, including migratory leukocytes. Although mammary antibody-secreting cells have been extensively studied, reports focusing on mammary T cells are scarce. It is thought that the recruitment mechanism of leukocytes to the mammary gland (MG) is controlled by pregnancy- and lactation-specific stimuli. But whether prolactin (PRL) modulates the T-cell population in MG is still unknown. Our aim was to study the relationship between PRL levels and T and B cells during early lactation (L2, day 2 post partum) and mid-lactation (L12, day 12 of lactation). In order to investigate whether PRL is associated with homing events to MG, female Sprague Dawley (SD) and SD-derived desmoglein 4(-/-) hairless (phenotype with lactation deficit, OFA hr/hr) rats were killed during estrus, pregnancy, and post partum, and blood, MG, and corpora lutea were obtained to perform fluorescent-activated cell sorting (FACS), real-time PCR, and histological and RIA studies. Serum PRL levels were lower in OFA hr/hr rats than in SD rats during early lactation. MG of OFA hr/hr rats showed less secretory material compared with SD rats. FACS analysis showed lower percentage of MG CD3+ cells in OFA hr/hr rats compared with SD rats on L2 and L12. OFA hr/hr rats showed higher absolute numbers of circulating CD3+ cells compared with SD rats on L2 but not on L12. These results show that T-cell population in MG is affected in early lactating OFA hr/hr rats and strongly suggest that serum PRL levels may be involved in the homing events to MG, probably helping antibody-secreting cells and protecting the gland during lactation development.


Subject(s)
Lactation , Mammary Glands, Animal/immunology , Prolactin/physiology , T-Lymphocytes/physiology , Animals , B-Lymphocytes/physiology , Female , Leukocytes/metabolism , Lymphocyte Count , Male , Mammary Glands, Animal/growth & development , Pregnancy , Rats , Rats, Sprague-Dawley , Receptors, Chemokine/metabolism
17.
J Mol Diagn ; 14(6): 613-22, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22925694

ABSTRACT

Breast carcinogenesis is a multistep process that involves both genetic and epigenetic alterations. Identification of aberrantly methylated genes in breast tumors and their relation to clinical parameters can contribute to improved diagnostic, prognostic, and therapeutic decision making. Our objective in the present study was to identify the methylation status of 34 cancer-involved genes in invasive ductal carcinomas (IDC). Each of the 70 IDC cases analyzed had a unique methylation profile. The highest methylation frequency was detected in the WT1 (95.7%) and RASSF1 (71.4%) genes. Hierarchical cluster analysis revealed three clusters with different distribution of the prognostic factors tumor grade, lymph node metastasis, and proliferation rate. Methylation of TP73 was associated with high histological grade and high proliferation rate; methylation of RARB was associated with lymph node metastasis. Concurrent methylation of TP73 and RARB was associated with high histological grade, high proliferation rate, increased tumor size, and lymph node metastasis. Patients with more than six methylated genes had higher rates of relapse events and cancer deaths. In multivariate analysis, TP73 methylation and the methylation index were associated with disease outcome. Our results indicate that methylation index and methylation of TP73 and/or RARB are related to unfavorable prognostic factors in patients with IDC. These epigenetic markers should be validated in further studies to improve breast cancer management.


Subject(s)
Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , CpG Islands , DNA Methylation , Gene Expression Regulation, Neoplastic , Adult , Breast/metabolism , Breast/pathology , Breast Neoplasms/diagnosis , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Ductal, Breast/pathology , Cluster Analysis , DNA-Binding Proteins/genetics , Female , Humans , Middle Aged , Nuclear Proteins/genetics , Prognosis , Receptors, Retinoic Acid/genetics , Tumor Protein p73 , Tumor Suppressor Proteins/genetics , WT1 Proteins/genetics
18.
Int J Hyperthermia ; 28(3): 191-201, 2012.
Article in English | MEDLINE | ID: mdl-22515340

ABSTRACT

PURPOSE: The objective of the present study was to examine the consequences of a mild hyperthermia in human tumour cell lines deficient and proficient in the DNA mismatch repair system (MMR) to advance our understanding on the relationship between MMR and heat shock proteins (HSPs). MATERIALS AND METHODS: The human colon carcinoma cell lines HCT116 (parent cells), HCT116 + ch2 (MMR-deficient), and HCT116 + ch3 (MMR-proficient) were used. Cells were incubated at 41°C and 42°C for 1 h and then at 37°C for 4 and 24 h. The expression of Hsp27 and Hsp72 was evaluated by immunocytochemistry. Hsp27, Hsp72, hMLH1 and hMSH2 levels were assessed by western blotting in nuclear and cytoplasmic fractions. The alkaline comet assay was used to evaluate the DNA damage. RESULTS: The mild hyperthermia significantly increased the protein expression levels of Hsp27 and Hsp72 in all cell lines, which was higher in the cytoplasm and nucleus of HCT116 + ch3 cells. We also observed that heat induced translocation of hMLH1 and hMSH2 proteins from the nucleus to the cytoplasm in HCT116 + ch3 cells. The comet assay revealed that HCT116 parent cells were more resistant to heat-induced DNA damage. However, the MMR-proficient and deficient cell lines repaired the DNA damage at the same rate. CONCLUSIONS: The present study demonstrates that hyperthermia induced the nuclear accumulation of Hsp27 and Hsp72 and affected the subcellular localisation of hMLH1 and hMSH2 in HCT116 + ch3 cells. Our findings suggest that the MMR system is not a direct determining factor for the different heat shock response in HCT116 cells.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , DNA Mismatch Repair , HSP27 Heat-Shock Proteins/metabolism , HSP70 Heat-Shock Proteins/metabolism , Hyperthermia, Induced , MutS Homolog 2 Protein/metabolism , Nuclear Proteins/metabolism , Adaptor Proteins, Signal Transducing/genetics , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , HCT116 Cells , Heat-Shock Proteins , Humans , Molecular Chaperones , MutL Protein Homolog 1 , MutS Homolog 2 Protein/genetics , Nuclear Proteins/genetics
19.
Ciudad Autónoma de Buenos Aires; Ministerio de Salud de la Nación; 2012. 1 p.
Non-conventional in Spanish | ARGMSAL, BINACIS | ID: biblio-1555413

ABSTRACT

INTRODUCCIÓN La preeclampsia es una patología del embarazo, etiología desconocida con morbimortalidad materno-perinatal. OBJETIVOS Evaluar los marcadores moleculares Activina A, PAPP-A, PP13 e Inhibina A. Detectar precozmente cuáles son las mujeres con alto riesgo de desarrollar preeclampsia, generar un banco de muestras de sangre, determinar los marcadores en los tres trimestres y establecer si son predictivos y se relacionan con la enfermedad. MÉTODOS Se incorporó a mujeres con embarazo normal y no embarazadas. Se tomaron muestras de sangre entre las semanas 10-12 y 17-20 del embarazo y en el parto. Las muestras fueron alicuotadas y almacenadas a -80 ºC hasta su utilización. Se dosificaron los marcadores por técnica ELISA con kits comerciales. RESULTADOS La concentración de Activina A se incrementó en el primer trimestre en las pacientes con preeclampsia leve. Se observó una disminución en la concentración de PAPP-A en el primer trimestre en las pacientes con desarrollo de preeclampsia, una disminución de PP13 en el primer y el segundo trimestres en las pacientes con preeclampsia leve estadísticamente significativa en el primer trimestre (p=0,038) y una disminución de Inhibina A en el tercer trimestre en las pacientes con preeclampsia severa (p=0,014). DISCUSIÓN La determinación de PP13 en el primer trimestre del embarazo es útil para la predicción de preeclampsia leve. Los resultados hallados son discordantes con los de otros autores que también encuentran diferencias significativas en las concentraciones de los marcadores Activina A, PAPP-A e Inhibina A.


Subject(s)
Pre-Eclampsia , Pregnancy-Associated Plasma Protein-A
20.
J Med Case Rep ; 5: 516, 2011 Oct 18.
Article in English | MEDLINE | ID: mdl-22011321

ABSTRACT

INTRODUCTION: Giant fibroadenoma is an uncommon variant of benign breast lesions. Aberrant methylation of CpG islands in promoter regions is known to be involved in the silencing of genes (for example, tumor-suppressor genes) and appears to be an early event in the etiology of breast carcinogenesis. Only hypermethylation of p16INK4a has been reported in non-giant breast fibroadenoma. In this particular case, there are no previously published data on epigenetic alterations in giant fibroadenomas. Our previous results, based on the analysis of 49 cancer-related CpG islands have confirmed that the aberrant methylation is specific to malignant breast tumors and that it is completely absent in normal breast tissue and breast fibroadenomas. CASE PRESENTATION: A 13-year-old Hispanic girl was referred after she had noted a progressive development of a mass in her left breast. On physical examination, a 10 × 10 cm lump was detected and axillary lymph nodes were not enlarged. After surgical removal the lump was diagnosed as a giant fibroadenoma. Because of the high growth rate of this benign tumor, we decided to analyze the methylation status of 49 CpG islands related to cell growth control. We have identified the methylation of five cancer-related CpG islands in the giant fibroadenoma tissue: ESR1, MGMT, WT-1, BRCA2 and CD44. CONCLUSION: In this case report we show for the first time the methylation analysis of a giant fibroadenoma. The detection of methylation of these five cancer-related regions indicates substantial epigenomic differences with non-giant fibroadenomas. Epigenetic alterations could explain the higher growth rate of this tumor. Our data contribute to the growing knowledge of aberrant methylation in breast diseases. In this particular case, there exist no previous data regarding the role of methylation in giant fibroadenomas, considered by definition as a benign breast lesion.

SELECTION OF CITATIONS
SEARCH DETAIL
...